Neuren Pharmaceuticals Limited
Appendix 4D
Half-year report

1. Company details

Name of entity:	Neuren Pharmaceuticals Limited
ARBN:	111 496 130
Reporting period:	For the half-year ended 30 June 2025
Previous period:	For the half-year ended 30 June 2024

2. Results for announcement to the market

	2025 $'000	2024 $'000	Change $'000	Change %
Revenues from ordinary activities	39,723	32,106	7,617	24%
Profit from ordinary activities after tax attributable to the owners of Neuren Pharmaceuticals Limited	15,031	8,016	7,015	88%
Profit for the half-year attributable to the owners of Neuren Pharmaceuticals Limited	15,031	8,016	7,015	88%

	2025 Cents	2024 Cents
Basic earnings per share	11.88	6.28
Diluted earnings per share	11.65	6.13

Dividends
There were no dividends paid, recommended or declared during the current financial period.

Comments
The profit after income tax for the half-year ended 30 June 2025 was A$15.0 million, compared with a net profit after tax of A$8.0 million for the half-year ended 30 June 2024.

Royalty revenue from Acadia increased to A$28.3 million from A$24.3 million in the half-year ended 30 June 2024.

For further commentary on the Company's results, please refer to the accompanying ASX release and the Directors' report within the Interim Report. This information should be read in conjunction with the most recent Annual Report (for the financial year ended 31 December 2024).

3. Net tangible assets

	As at 30 Jun 2025 Cents	As at 31 Dec 2024 Cents
Net tangible assets per ordinary security	247.87	273.52

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

Neuren Pharmaceuticals Limited
Appendix 4D
Half-year report

6. Dividends and other shareholder distributions

Current period
There were no dividends paid, recommended or declared during the current financial period.

During the half-year ended 30 June 2025, Neuren completed on-market buy-backs totalling $39.6 million. Neuren purchased 3,273,098 ordinary shares on issue at the average price of $12.09. The share buy-back program concluded on 16 June 2025.

Previous period
There were no dividends paid, recommended or declared during the previous financial period.

---

7. Dividend reinvestment plans

Not applicable.

---

8. Details of associates and joint venture entities

Not applicable.

---

9. Accounting standards

The interim financial statements have been prepared in accordance with *International Accounting Standard 34* and NZ IAS 34 *Interim Financial Reporting*.

---

10. Auditors review

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

---

11. Attachments

Details of attachments (if any):

The Interim Report of Neuren Pharmaceuticals Limited for the half-year ended 30 June 2025 is attached.

---

12. Signed

Signed  Date: 26 August 2025

Patrick Davies
Non-Executive Chair
Melbourne

Neuren Pharmaceuticals Limited

ARBN 111 496 130

Consolidated Interim Financial Report for the Half-Year ended 30 June 2025

Neuren Pharmaceuticals Limited
Contents
30 June 2025

Neuren Pharmaceuticals Limited
Directors' report
30 June 2025

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Neuren Pharmaceuticals Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 30 June 2025.

Directors
The following persons were directors of Neuren Pharmaceuticals Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Patrick Davies (Non-Executive Chair)
Jonathan Pilcher (Chief Executive Officer/Managing Director)
Dianne Angus (Non-Executive Director)
Dr Jenny Harry (Non-Executive Director)
Joe Basile (Non-Executive Director)

Principal activities
During the financial half-year the principal continuing activities of the consolidated entity consisted of:
- Development of pharmaceutical products for the treatment of neurodevelopmental disorders
- Royalty revenue from licence of intellectual property

Review of operations
Neuren Pharmaceuticals Limited ("Neuren" or the "Company"), and its subsidiaries (collectively the "Group") is a biopharmaceutical company, incorporated in New Zealand and listed on the Australian Securities Exchange (ASX: NEU). Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood.

Trofinetide

In April 2023, Neuren's worldwide partner for trofinetide, Acadia Pharmaceuticals (NASDAQ: ACAD) launched DAYBUE™ (trofinetide) in the United States as the first approved treatment for Rett syndrome.

DAYBUE™ net sales for the half-year to 30 June 2025 were US$180.7 million, delivering royalties of A$28.3 million to Neuren. The number of unique patients receiving a DAYBUE shipment continued to grow and in Q2 2025 reached a record high of 987, up from 954 in Q1 2025 and 920 in Q4 2024. The persistency rate remains steady above 50% after 12 months of treatment. 70% of active patients have now been on therapy for 12 months or longer. There is substantial potential for future growth in the US with two-thirds of the 5,500 to 5,800 diagnosed Rett patients yet to try DAYBUE. During the half-year, Acadia completed the planned expansion of its DAYBUE field force in the US by ~30% to accelerate future growth in the community outside the Rett syndrome centres of excellence. In Q2 2025, approximately three-quarters of new patient referrals came from the community.

Acadia has provided guidance for full-year net sales in 2025 of US$380-405 million. Assuming this guidance is met and an exchange rate of 0.65, Neuren anticipates earning full-year royalties of A$62-67 million.

In January 2025, Acadia submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. Acadia anticipates potential marketing authorisation in Q1 2026 and continues to build its European commercialisation team. If granted marketing authorisation, trofinetide will be the first and only approved therapy for Rett syndrome in the European Union. In the meantime, the first shipment of DAYBUE was made to a Rett syndrome patient in Germany in April 2025 under a managed access program.

In Japan, trofinetide received Orphan Drug Designation and Acadia is on track to commence the planned clinical trial in Japan in Q3 2025. Acadia has also entered into distribution agreements to facilitate named patient supply in other regions including Latin America, Middle East and Asia Pacific.

NNZ-2591

Neuren is developing a second drug NNZ-2591 for multiple serious neurodevelopmental disorders with different genetic origins that have no or limited approved treatment options. Recognising the urgent unmet need, programs have been granted “orphan drug” designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

In 2024, Neuren achieved positive top-line results from the Phase 2 clinical trials of NNZ-2591 in children with Phelan-McDermid syndrome (PMS), Pitt Hopkins syndrome (PTHS) and Angelman syndrome (AS).

In April 2025, Neuren confirmed the primary endpoints for a single Phase 3 pivotal clinical trial of NNZ-2591 in PMS at a Type C Meeting with the US Food and Drug Administration (FDA).The co-primary endpoints in the double-blind placebo-controlled study of treatment for 13 weeks will be the change from baseline in the Receptive Communication sub-domain of the Vineland Adaptive Behavior Scales, Third Edition (VABS-3 Receptive-Raw Score) and the overall score in the Phelan-McDermid Syndrome Assessment of Change (PMSA-C, previously referred to as CGI-I in Neuren’s Phase 2 trial). Both measures were robustly positive with clinically meaningful improvement in Neuren’s Phase 2 open-label clinical trial. 16 out of 18 children showed improvement measured by the VABS-3 Receptive-Raw Score, with mean improvement of 7.5 from a mean baseline of 29.0 (Wilcoxon signed rank test $p=0.0001$) and 16 out of 18 children showed improvement from baseline measured by the PMSA-C with a mean score of 2.4 (Wilcoxon signed rank test $p<0.0001$).

The endpoints pair the caregiver’s assessment of change in one important symptom area with the clinician’s assessment of change across multiple aspects of PMS. Communication is one of the most impactful health concerns in PMS reported by caregivers. Receptive communication, as measured by VABS-3 Receptive-Raw Score, is the ability to receive and understand non-verbal and verbal interactions which is a foundational skill for the development of learning, social interaction, and speech.

Alignment with FDA was previously reached on the other key features of the Phase 3 program at an End of Phase 2 Meeting. Neuren recently announced initiation of the first US investigational site in the US for the trial, with other sites in the US at various stages of the initiation process. Neuren’s financial strength means that no additional funding is required to execute the program.

Neuren also added two new indications, hypoxic-ischemic encephalopathy (HIE) and *SYNGAP1*-related disorder (SRD) into its neurodevelopmental disorders pipeline for NNZ-2591.

HIE is a devastating type of brain injury caused when a baby’s brain does not receive enough oxygen or blood flow before or shortly after birth. Many thousands of babies and children experience HIE every year. It is one of the leading causes of neonatal death and neurodevelopmental disability worldwide.

HIE can lead to a range of symptoms in surviving children, including developmental delays, cognitive impairment, cerebral palsy, and seizures. Some children develop serious long-term complications that can affect them well into adulthood. Currently, the only approved treatment for HIE is temporary hypothermia (cooling the head or whole body to lower the baby’s metabolic rate and give the brain some time to recover from the hypoxic event). Hypothermia provides a modest decrease in mortality and severe neurodevelopmental disability, however even with hypothermia, 40-45% of children who survive HIE have significant neurodevelopmental impairment at 2 years of age.

Based on its therapeutic properties and data from a range of preclinical models, Neuren believes that NNZ-2591 can potentially provide a highly differentiated form of treatment continuing beyond acute treatment in the neonatal intensive care unit to target both the acute effects and chronic impairments resulting from HIE.

SRD is caused by a variant on the *SYNGAP1* gene located on Chromosome 6, which is responsible for producing the SYNGAP1 protein. The protein acts as a regulator in the synapses and insufficient production leads to impaired communication between neurons. This results in the many neurological issues seen in *SYNGAP1* patients, including intellectual disability, low muscle tone, global development delay, epilepsy, sensory processing disorder, gross and fine motor skill delays, coordination disorder, speech delay, sleep and behavior disorder and autism spectrum disorder.

In an in-vitro model of SRD in human iPSC-derived neurons, treatment with NNZ-2591 reversed the neuronal dysfunction caused by *SYNGAP1* haploinsufficiency.

Financial commentary

The consolidated interim financial statements for the half-year are presented on pages 6 to 16. All amounts in the Financial Statements are shown in Australian dollars unless otherwise stated.

The Group's net profit after income tax for the half-year ended 30 June 2025 was A$15.0 million, compared with a net profit after tax of A$8.0 million for the half-year ended 30 June 2024. Royalty revenue of A$28.3 million was earned under the license agreement with Acadia (30 June 2024: A$24.3 million). Other income includes interest income of A$6.3 million (30 June 2024: A$5.8 million) and a foreign currency gain of A$5.2 million mainly due to the translation of cash and short-term investments held in Australian dollars to the US dollars functional currency.

Research and development costs decreased by A$3.0 million to A$14.9 million, with higher expenditure for the half-year ended 30 June 2024 due to completion of the NNZ-2591 Phase 2 clinical trials as well as foundational work to prepare for Phase 3 development of NNZ-2591. Costs for the half-year ended 30 June 2025 include start-up costs for the Phase 3 trial of NNZ-2591 in PMS.

Corporate and administrative costs of A$2.5 million remained consistent with the prior period. A loss of A$2.6 million on the fair value of outstanding forward contracts to sell Australian dollars and buy US dollars was recognised at 30 June 2025 (30 June 2024: A$1.9 million gain). Income tax expense recognised for the half-year ended 30 June 2025 was A$4.7 million (30 June 2024: A$3.8 million).

The basic earnings per share for the half-year to 30 June 2025 was A$0.1188 (half-year to 30 June 2024: earnings per share A$0.0628) based on a weighted average number of shares outstanding of approximately 126.6 million (half-year to 30 June 2024: 127.7 million).

Total cash and short-term investments at 30 June 2025 were A$299.5 million (31 December 2024: A$222.2 million). Net cash generated from operating activities was A$128.3 million, compared with net cash used of A$20.5 million for half-year to 30 June 2024. This is mainly due to receipts from license agreements, with receipt of the first sales milestone and share of priority review voucher sale proceeds, both of which were earned in Q4 2024 and received in Q1 2025. The receipts from license agreements for the half-year to 30 June 2024 included only the receipt of quarterly royalties. Net cash used in financing activities was A$38.2 million, comprising A$39.6 million of payments for the share buy-back, offset by A$1.4 million of proceeds received on conversion of loan funded shares.

Neuren Pharmaceuticals Limited
Directors' declaration
30 June 2025

The Directors of Neuren Pharmaceuticals Limited ("Neuren") declare that:

The accompanying consolidated interim financial statements of Neuren and its subsidiaries for the half-year ended 30 June 2025 and the notes to those consolidated interim financial statements:

· comply with International Accounting Standard 34 and NZ IAS 34 *Interim Financial Reporting*; and

· present fairly, in all material respects, the financial position as at 30 June 2025 and of the performance for the half-year ended on that date of Neuren and its subsidiaries.

In the Directors' opinion there are reasonable grounds to believe that Neuren will be able to pay its debts as and when they become due and payable.

This report is signed and the declaration is made in accordance with a resolution of the Board of Directors dated 26 August 2025.

On behalf of the directors

Patrick Davies
Non-Executive Chair

Joe Basile
Non-Executive Director

26 August 2025
Melbourne

Neuren Pharmaceuticals Limited
Consolidated interim statement of profit or loss and other comprehensive income
For the half-year ended 30 June 2025

	Note	Half year ended Jun 2025 $'000	Half year ended Jun 2024 $'000
Revenue from contracts with customers	6	28,277	24,327
Finance income		6,293	5,836
Net foreign currency gains		5,153	23
Gain on financial derivatives measured at fair value through profit and loss		-	1,920
Total income		39,723	32,106
Expenses			
Research and development costs		(14,897)	(17,889)
Corporate and administrative costs		(2,483)	(2,374)
Loss on financial derivatives measured at fair value through profit and loss		(2,622)	-
Total expenses		(20,002)	(20,263)
Profit before income tax expense		19,721	11,843
Income tax expense	7	(4,690)	(3,827)
Profit after income tax expense for the half-year attributable to the owners of Neuren Pharmaceuticals Limited		15,031	8,016
Other comprehensive (loss)/income			
Items that may be reclassified subsequently to profit or loss			
Foreign currency translation		(17,969)	3,513
Other comprehensive (loss)/income for the half-year, net of tax		(17,969)	3,513
Total comprehensive (loss)/income for the half-year attributable to the owners of Neuren Pharmaceuticals Limited		(2,938)	11,529
		Cents	**Cents**
Basic earnings per share	3	11.88	6.28
Diluted earnings per share	3	11.65	6.13

The above consolidated interim statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Neuren Pharmaceuticals Limited
Consolidated interim statement of financial position
As at 30 June 2025

	Note	As at 30 Jun 2025 $'000	As at 31 Dec 2024 $'000
Assets			
Current assets			
Cash and cash equivalents		5,906	3,153
Short term investments		293,631	219,089
Trade and other receivables		6,518	157,967
Contract assets		14,004	17,756
Derivative financial instruments		-	1,362
Income tax receivable		187	-
Total current assets		320,246	399,327
Non-current assets			
Plant and equipment		25	31
Deferred tax asset		10,981	10,348
Total non-current assets		11,006	10,379
Total assets		331,252	409,706
Liabilities			
Current liabilities			
Trade and other payables		6,663	2,895
Derivative financial instruments		1,260	-
Income tax payable		-	42,866
Total current liabilities		7,923	45,761
Non-current liabilities			
Employee benefits		55	41
Total non-current liabilities		55	41
Total liabilities		7,978	45,802
Net assets		323,274	363,904
Equity			
Share capital	8	127,591	165,270
Share option reserve		4,682	4,695
Currency translation reserve		(4,461)	13,508
Retained earnings		195,462	180,431
Total equity		323,274	363,904

The above consolidated interim statement of financial position should be read in conjunction with the accompanying notes

Neuren Pharmaceuticals Limited
Consolidated interim statement of changes in equity
For the half-year ended 30 June 2025

	Share capital $'000	Share option reserve $'000	Currency translation reserve $'000	Retained earnings $'000	Total equity $'000
Balance at 1 January 2024	173,127	4,382	(10,690)	38,388	205,207
Profit after income tax expense for the half-year	-	-	-	8,016	8,016
Other comprehensive income for the half-year, net of tax	-	-	3,513	-	3,513
Total comprehensive income for the half-year	-	-	3,513	8,016	11,529
Transactions with owners in their capacity as owners:					
Loan funded shares converted	277	-	-	-	277
Share-based payments	-	765	-	-	765
Transfer on conversion of loan funded shares and options	918	(918)	-	-	-
Share options exercised	1,383	-	-	-	1,383
Issue costs on conversion of loan funded shares	(9)	-	-	-	(9)
Balance at 30 June 2024	175,696	4,229	(7,177)	46,404	219,152

	Share capital $'000	Share option reserve $'000	Currency translation reserve $'000	Retained earnings $'000	Total equity $'000
Balance at 1 January 2025	165,270	4,695	13,508	180,431	363,904
Profit after income tax expense for the half-year	-	-	-	15,031	15,031
Other comprehensive loss for the half-year, net of tax	-	-	(17,969)	-	(17,969)
Total comprehensive (loss)/income for the half-year	-	-	(17,969)	15,031	(2,938)
Transactions with owners in their capacity as owners:					
On-market share buy-back	(39,573)	-	-	-	(39,573)
Loan funded shares converted	1,380	-	-	-	1,380
Share based payments	-	512	-	-	512
Transfer on conversion of loan funded shares and options	525	(525)	-	-	-
Issue costs on conversion of loan funded shares	(11)	-	-	-	(11)
Balance at 30 June 2025	127,591	4,682	(4,461)	195,462	323,274

The above consolidated interim statement of changes in equity should be read in conjunction with the accompanying notes

Neuren Pharmaceuticals Limited
Consolidated interim statement of cash flows
For the half-year ended 30 June 2025

	Note	Half year ended Jun 2025 $'000	Half year ended Jun 2024 $'000
Cash flows from operating activities			
Receipts from license agreement		191,340	24,429
Income tax paid		(46,973)	(34,163)
Withholding tax paid		(5,636)	(1,222)
Interest received		5,800	5,929
GST refunded		135	221
Payments for employees and directors		(1,988)	(2,193)
Payments to other suppliers		(14,372)	(13,537)
Net cash from/(used in) operating activities	4	128,306	(20,536)
Cash flows from investing activities			
Purchase of plant and equipment		(5)	(3)
Less cash transferred (to)/from short-term investments (i)		(85,568)	843
Net cash (used in)/from investing activities		(85,573)	840
Cash flows from financing activities			
Proceeds from issue of shares		1,380	1,660
Payment of share issue expenses		(15)	(9)
Payments for share buy-back		(39,573)	-
Net cash (used in)/from financing activities		(38,208)	1,651
Net increase/(decrease) in cash and cash equivalents		4,525	(18,045)
Cash and cash equivalents at the beginning of the financial half-year		3,153	17,094
Effects of exchange rate changes on cash and cash equivalents		(1,772)	3,522
Cash and cash equivalents at the end of the financial half-year		5,906	2,571

(i) The Company has reclassified cash held in short-term deposits from Cash and Cash Equivalents to Short-term Investments.

The above consolidated interim statement of cash flows should be read in conjunction with the accompanying notes

Neuren Pharmaceuticals Limited
Notes to the consolidated interim financial statements
30 June 2025

Note 1. Nature of the business

Neuren Pharmaceuticals Limited ("Neuren" or the "Company"), and its subsidiaries (collectively the "Group") is a publicly listed biopharmaceutical company developing drugs for neurological disorders.

The Company is a limited liability company incorporated in New Zealand. The address of its registered office in New Zealand is at the offices of Lowndes Jordan, Level 15 HSBC Tower, 188 Quay Street, Auckland 1141. Neuren operates in Australia and its ordinary shares are listed on the Australian Securities Exchange (ASX code: NEU).

These consolidated interim financial statements were approved for issue by the Board of Directors on 26 August 2025.

Note 2. Material accounting policy information

Basis of preparation
These condensed consolidated interim financial statements are for the half-year ended 30 June 2025 and have been prepared in accordance with, and comply with International Accounting Standard 34 and NZ IAS 34 *Interim Financial Reporting*.

The Group is a Tier 1 for-profit entity under the External Reporting Board Accounting Standards Framework in New Zealand.

New or amended Accounting Standards and Interpretations adopted
There have been no significant changes in accounting policies during the current period. The accounting policies that materially affect the measurement of the Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income, Consolidated Interim Statement of Financial Position, Consolidated Interim Statement of Changes in Equity and the Consolidated Interim Statement of Cash Flows have been applied on a basis consistent with those used in the audited financial statements for the year ended 31 December 2024 and the unaudited interim financial statements for the half-year ended 30 June 2024.

There is no cyclical seasonality of interim operations.

The presentation currency of the Group is Australian dollars and the functional currency is US dollars.

These interim financial statements do not include all the notes of the type normally included in an annual financial report. Accordingly, this interim report is to be read in conjunction with the annual report for the year ended 31 December 2024.

Comparatives
Where deemed necessary, the comparatives have been reclassified to achieve consistency with the current financial half-year.

Note 3. Earnings per share

Basic earnings per share is calculated by dividing the profit for the period attributable to the equity holders of the company by the weighted average number of ordinary shares on issue during the period excluding shares held as treasury stock.

Diluted earnings per share is calculated by dividing the profit attributable to ordinary equity holders of the company by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

	Half year ended Jun 2025 $'000	Half year ended Jun 2024 $'000
Profit after income tax attributable to the owners of Neuren Pharmaceuticals Limited	15,031	8,016
	Number	**Number**
Weighted average number of ordinary shares used in calculating basic earnings per share	126,576,586	127,674,028
Adjustments for calculation of diluted earnings per share:		
Options over ordinary shares	2,414,558	3,145,014
Weighted average number of ordinary shares used in calculating diluted earnings per share	128,991,144	130,819,042
	Cents	**Cents**
Basic earnings per share	11.88	6.28
Diluted earnings per share	11.65	6.13

Note 4. Reconciliation of profit after income tax to net cash from/(used in) operating activities

	Half year ended Jun 2025 $'000	Half year ended Jun 2024 $'000
Profit after income tax expense for the half-year	15,031	8,016
Adjustments for:		
Depreciation of property, plant and equipment	11	11
Share based payments expense	512	765
Foreign exchange (gain)/loss	(5,153)	20
Unrealised loss/(gain) on derivative financial instruments	2,622	(1,920)
Change in working capital:		
Decrease in trade and other receivables	151,449	3,749
Decrease in contract assets	3,752	-
(Decrease) in current and deferred taxes	(43,686)	(32,235)
Increase in trade and other payables	3,768	1,058
Net cash from/(used in) operating activities	128,306	(20,536)

Note 5. Operating segments

Identification of reportable operating segments
The segment reporting reflects the way information is reported internally to the chief operating decision maker. The Board of the Group has been identified as the chief operating decision maker. The Board assesses the financial performance and position of the group and makes strategic decisions. The Group has two reportable operating segments, commercial products and research and development.

Reportable segment	Principal activities
Commercial products	Milestone and royalty revenue from licence of intellectual property.
Research & development	Development of pharmaceutical products for the treatment of neurodevelopmental disorders.

	Commercial products		Research & development		Corporate		Total	
	Jun-25 $'000	Jun-24 $'000	Jun-25 $'000	Jun-24 $'000	Jun-25 $'000	Jun-24 $'000	Jun-25 $'000	Jun-24 $'000
Revenue	28,277	24,327	-	-	-	-	28,277	24,327
Research and development costs	-	-	(14,897)	(17,889)	-	-	(14,897)	(17,889)
Finance income	-	-	-	-	6,293	5,836	6,293	5,836
Net foreign currency gain	-	-	-	-	5,153	23	5,153	23
(Loss)/gain on financial derivatives	-	-	-	-	(2,622)	1,920	(2,622)	1,920
Other expenses	-	-	-	-	(2,483)	(2,374)	(2,483)	(2,374)
Profit before income tax	**28,277**	**24,327**	**(14,897)**	**(17,889)**	**6,341**	**5,405**	**19,721**	**11,843**
Income tax expense	-	-	-	-	(4,690)	(3,827)	(4,690)	(3,827)
Profit after income tax	**28,277**	**24,327**	**(14,897)**	**(17,889)**	**1,651**	**1,578**	**15,031**	**8,016**
Other comprehensive income	-	-	-	-	(17,969)	3,513	(17,969)	3,513
Total comprehensive income	**28,277**	**24,327**	**(14,897)**	**(17,889)**	**(16,318)**	**5,091**	**(2,938)**	**11,529**

All revenue from licences of intellectual property is from Acadia Pharmaceuticals Inc. (Acadia) and is received from the United States.

Assets and liabilities are not allocated to segments and are therefore not reported.

Note 6. Revenue from contracts with customers

Disaggregation of revenue from contracts with customers
The Group derives revenue from the sale of goods and services at a point in time under the following major business activities:

	Half year ended Jun 2025 $'000	Half year ended Jun 2024 $'000
Revenue from contracts with customers		
Licenses of intellectual property - royalty income	28,277	24,327

Note 6. Revenue from contracts with customers (continued)

All revenue from licences of intellectual property is received from the United States.

Neuren is eligible to receive quarterly royalty income, calculated as a percentage of net sales of DAYBUE in North America and is recognised in the period the Acadia makes the sales of DAYBUE. The royalty rate for ≤US$250 million of annual net sales is 10%. The royalty rate then increases to 12% for annual net sales greater than US$250 million but less than or equal to US$500 million.

Neuren is also eligible to receive future milestone payments of up to US$300 million on achievement of a series of three thresholds of total annual net sales.

Note 7. Income tax

Income tax expense is recognised based on management's estimate of the weighted average effective annual income tax rate expected for the full financial year. The estimated average annual tax rate used for the half-year ended 30 June 2025 is 30%.

	Half year ended Jun 2025 $'000	Half year ended Jun 2024 $'000
Income tax expense		
Current tax	5,039	2,994
Deferred tax - origination and reversal of temporary differences	(587)	700
Under provision in prior years	238	133
Aggregate income tax expense	4,690	3,827
Deferred tax included in income tax expense comprises:		
Decrease/(increase) in deferred tax assets	(587)	700
Numerical reconciliation of income tax expense and tax at the statutory rate		
Profit before income tax expense	19,721	11,843
Tax at the statutory tax rate of 30%	5,916	3,553
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:		
Research and development incentives	-	(181)
Share-based payments	154	230
Non-assessable income	(1,360)	-
Other	43	96
	4,753	3,698
Under provision in prior years	238	133
Utilisation of carried forward tax losses	(269)	-
Difference in overseas tax rates	(32)	(4)
Income tax expense	4,690	3,827

Note 8. Share capital

	Half-year ended 30 June 2025 Shares	Year ended 31 December 2024 Shares	Half-year ended 30 June 2025 $'000	Year ended 31 December 2024 $'000
Ordinary shares - issued	125,989,526	129,262,624	127,591	165,270

Note 8. Share capital (continued)

Ordinary shares
At 30 June 2025, 124,489,526 ordinary shares (31 December 2024: 127,012,624) are quoted on the ASX, and 1,500,000 unquoted ordinary shares (31 December 2024: 2,250,000) were held as treasury stock in respect of the Loan Funded Share Plan described below. On 2 December 2024 Neuren commenced a share buy-back program, buying back 3,273,098 shares in the half year period to 30 June 2025. The share buy-back program concluded on 16 June 2025, with total consideration paid for the share buy-back of $50.0 million since 2 December 2024.

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share based payments
During the half-year to 30 June 2025 $0.51 million (30 June 2024: $0.77 million) was recognised in share-based payments expense.

Loan funded shares
At 30 June 2025 1.5 million Loan Funded Shares are held in trust, of which all are vested. During the half-year ended 30 June 2025, 750,000 vested loan funded shares were converted to issued ordinary shares upon repayment of the loan.

Movements in the number of Loan Funded Shares were as follows:

	Loan funded shares	Weighted average exercise price
Outstanding at 31 December 2024	2,250,000	$1.84
Loan repaid and shares transferred to participant	(750,000)	$1.84
Outstanding at 30 June 2025	1,500,000	$1.84
Vested and exercisable at 30 June 2025	1,500,000	$1.84

The weighted average exercise price for the 1.5 million Loan Funded Shares is $1.84 per share.

Options to acquire ordinary shares
At 30 June 2025, there are 3.16 million options to acquire ordinary shares on issue to employees and consultants. During the half-year ended 30 June 2025, 70,000 options to acquire ordinary shares were forfeited due to service conditions not being met.

On 23 May 2025, options to acquire 1,800,000 ordinary shares were granted to employees and consultants. Options to acquire ordinary shares vest subject to remaining an employee or consultant if and when the following non-market performance vesting conditions are met in respect of NNZ-2591:

i. One third of the Options shall vest on the last patient dosing in a Phase 3 clinical trial
ii. One third of the Options shall vest on the acceptance for filing of a marketing application, or execution of a material partnering transaction
iii. One third of the Options shall vest on the first patient dosing in a pivotal clinical trial for a second indication

Note 8. Share capital (continued)

Each of these vesting conditions shall be tested separately from the other vesting conditions.

The estimated fair value of the options to acquire ordinary shares has been determined using the Black-Scholes valuation model. The significant inputs into the model were the share price on date of valuation, the estimated future volatility of the share price, the risk-free rate, the expected life and a dividend yield of 0%. The estimated future volatility of the share price was derived by analysing the historic volatility of the share price on a daily basis during the three years prior to the issue date of 23 May 2025, as this period is reflective of the anticipated volatility in the future.

Details of the options to acquire ordinary shares during the half year ended 30 June 2025, the estimated fair value and variable inputs into the valuation model are shown in the following tables:

Number of shares under option	1,800,000
Grant date	23 May 2025
Exercise price per share option[1]	$12.91
Share price on date of valuation	$12.87
Estimated future volatility	55.73%
Annual risk-free rate	3.69%

	Vesting condition (i)	Vesting condition (ii)	Vesting condition (iii)
Fair value per share option	$5.36	$5.93	$4.78
Expected life (years)	3.19	3.94	2.52

[1] The exercise price for the options to acquire ordinary shares is the 5-day weighted average price at which the shares were traded on the ASX in the 5 days preceding the issue of the options.

In addition, the Board resolved to issue options to acquire 360,000 ordinary shares for CEO & Managing Director Jon Pilcher which are subject to shareholder approval and will not be issued prior to receiving approval at a future meeting of shareholders. If approved, the options to acquire ordinary shares will be subject to the same vesting conditions as the above options to acquire 1,800,000 ordinary shares issued on 23 May 2025. As the services received from Jon Pilcher in respect of the proposed grant of options have commenced, the fair value of the share options has been estimated using the Black-Scholes model. The significant inputs into the model were the same assumptions as the above options to acquire 1,800,000 ordinary shares granted on 23 May 2025. The fair value estimate will be revised once the grant date has been established, subject to shareholder approval.

Movements in the number of Share Options were as follows:

	Share options	Weighted average exercise price
Outstanding at 31 December 2024	1,430,000	$8.11
Granted during the year[2]	1,800,000	$12.91
Forfeited during the year	(70,000)	$23.09
Exercised during the year	-	-
Outstanding at 30 June 2025	3,160,000	$10.51
Vested and exercisable at 30 June 2025	1,100,000	3.61

The weighted average exercise price for the options to acquire ordinary shares is $10.51.

[2] The options to acquire 360,000 ordinary shares for CEO & Managing Director Jon Pilcher are subject to shareholder approval, therefore are not included in the number of share options granted during the year.

Note 9. Dividends

There were no dividends paid, recommended or declared during the current or previous financial half-year.

Note 10. Key management personnel disclosures

Key management personnel remuneration is disclosed in the annual financial report.

During the half year ended 30 June 2025, 300,000 vested loan funded shares were converted to issued ordinary shares upon repayment of the loan by key management personnel. There were 540,000 share options issued to key management personnel in the half year ended 30 June 2025.

Note 11. Commitments and contingencies

(a) Legal claims

The Group had no significant legal matter contingencies at 30 June 2025 (30 June 2024: nil).

(b) Commitments

The Group was not committed to the purchase of any property, plant or equipment or intangible assets as at 30 June 2025 (30 June 2024: nil).

As at 30 June 2025, the Group had commitments under product development contracts at the end of the reporting period but not recognised as liabilities amounting to approximately $45.2 million, including approximately US $29.4 million.

(c) Contingent liabilities

The Group had no contingent liabilities at 30 June 2025 (30 June 2024: nil) that require disclosure.

Note 12. Events after the reporting period

No matter or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Independent Auditor's Review Report

Grant Thornton New Zealand Audit Limited
L4, Grant Thornton House
152 Fanshawe Street
Auckland Central
Auckland 1010

T +64 9 308 2570
www.grantthornton.co.nz

To the Shareholders of Neuren Pharmaceuticals Limited

Report on the Review of the Consolidated Interim Financial Statements

Conclusion

We reviewed the consolidated interim financial statements (the "financial statements") of Neuren Pharmaceuticals Limited and its subsidiaries (the 'Group'), which comprise the consolidated interim statement of financial position as at 30 June 2025, and the consolidated interim statement of profit or loss and other comprehensive income, consolidated interim statement of changes in equity and the consolidated interim statement of cash flows for the six month period ended on that date, and a summary of material accounting policies and other explanatory information.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying financial statements on pages 6 to 16 do not present fairly, in all material respects, the consolidated interim financial position of Neuren Pharmaceuticals Limited as at 30 June 2025, and of its consolidated interim financial performance and consolidated interim cash flows for the six month period ended on that date, in accordance with New Zealand equivalent to International Accounting Standard 34: *Interim Financial Reporting ('NZ IAS 34')* issued in New Zealand by the New Zealand Accounting Standards Board.

Basis for Conclusion

We conducted our review in accordance with NZ SRE 2410 (Revised) *Review of Financial Statements Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Statements* section of our report. We are independent of the Neuren Pharmaceuticals Limited in accordance with the relevant ethical requirements in New Zealand relating to the audit of the annual financial statements, and we have fulfilled our other ethical responsibilities in accordance with these ethical requirements.

Other than in our capacity as assurance practitioner we have no relationship with, or interests in, Neuren Pharmaceuticals Limited.

Directors' Responsibilities for the Financial Statements

The Directors are responsible, on behalf of the Group, for the preparation and fair presentation of the financial statements in accordance with NZ IAS 34 issued in New Zealand by the New Zealand Accounting Standards Board, and for such internal control as the Directors determine is necessary to enable the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibilities for the Review of the Financial Statements

Our responsibility is to express a conclusion on the financial statements based on our review. NZ SRE 2410 (Revised) requires us to conclude whether anything has come to our attention that causes us to believe that the financial statements, taken as a whole, are not prepared in all material respects, in accordance with NZ IAS 34 issued in New Zealand by the New Zealand Accounting Standards Board.

A review of the financial statements in accordance with NZ SRE 2410 (Revised) is a limited assurance engagement. We perform procedures, consisting of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with International Standards on Auditing (New Zealand) and consequently does not enable us to obtain assurance that we might identify in an audit. Accordingly, we do not express an audit opinion on those financial statements.

Restriction on use of our review report

This review report on the financial statements is made solely to the shareholders, as a body. Our limited assurance work has been undertaken so that we might state to the shareholders, as a body, those matters which we are required to state to them in an independent review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Neuren Pharmaceuticals Limited and the shareholders, as a body, for our work, for this review report or for the conclusion we have formed.

Grant Thornton New Zealand Audit Limited

D Alamar

Partner

Auckland

26th August 2025